구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Bendamustine + Rituximab (Bendamustine + Rituximab) Roche / Genentech·Chronic Lymphocytic Leukemia 52 trials |
|---|---|
Overview Program | Bendamustine + Rituximab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Chronic Lymphocytic Leukemia |
Overview Indication | Marginal Zone Lymphoma(MZL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targets the B-cell antigen |
MoA Biomarker | biomarker data at diagnosis were included in the survival analysis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.. We hypothesized that a time-limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety an… |
Toxicology CRS | Reported |
Clinical Safety signal | Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.. We hypothesized that a time-limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety an… |
Clinical Selected reported efficacy | ORR 95% |
Clinical Reported ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT02596971 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02596971 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Bendamustine + Rituximab (Bendamustine + Rituximab) Roche / Genentech·Chronic Lymphocytic Leukemia 52 trials |
|---|---|
Overview Program | Bendamustine + Rituximab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Chronic Lymphocytic Leukemia |
Overview Indication | Marginal Zone Lymphoma(MZL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targets the B-cell antigen |
MoA Biomarker | biomarker data at diagnosis were included in the survival analysis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.. We hypothesized that a time-limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety an… |
Toxicology CRS | Reported |
Clinical Safety signal | Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.. We hypothesized that a time-limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety an… |
Clinical Selected reported efficacy | ORR 95% |
Clinical Reported ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT02596971 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02596971 |
추천 비교
추천 비교